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From 1990 to 2000, tuberculosis (TB) caused
an estimated 88 million new infections and 30
million deaths worldwide (1). In Peru, tuberculo-
sis is highly endemic; a shantytown in Lima had
an annual incidence of pulmonary tuberculosis of
364 per 100,000 population (2). Despite the
implementation of community-based treatment
and control programs in Peru (3), management of
the disease has been complicated by high rates of
multidrug-resistant (MDR) TB. In one study in
Peru, 4.5% of all reported cases were resistant
to isoniazid and rifampin (4). Nosocomial
spread of MDRTB has been reported in both
industrialized and developing countries and has
been linked to inadequate hospital infection
control practices (5-7).
We investigated the potential for nosocomial
spread of MDRTB in one city hospital in Lima.
We assessed the prevalence of TB among
hospitalized patients on a general medicine
ward, the rate of MDRTB and the extent to which
active pulmonary TB had been suspected in
patients at the time of admission.
Methods
Study Population and Design
The study was conducted from January to
December 1997 in the Arzobispo Loayza
Hospital, an urban public hospital in Lima, Peru.
This hospital was founded as a women’s hospital
in the eighteenth century and continues to serve
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developing countries, hospital control, a simple method of reducing the spread of
MDRTB, is neglected.
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a largely female patient population. We solicited
the participation of all patients admitted to one of
the hospital’s eight female internal medicine
wards (an open room with 30 beds) during the
study period. The most common admission
diagnoses over the year of study were
pneumonia, bronchiectasis, cardiac insufficiency,
TB, cellulitis, diabetes mellitus and chronic renal
failure. The study protocol was approved by the
institutional review boards of the Johns Hopkins
University and Loayza Hospital. All study
participants gave informed consent.
Patients who agreed to participate in the
study answered a brief questionnaire and
underwent physical examination. The medical
records were reviewed. A tuberculin skin test
(TST) (5 tuberculin units, Connaught, Swiftwater,
PA) was administered and was read after 48 to 72
hours. The TST was considered positive if the
area of induration measured >10 mm both
vertically and horizontally. At least one sputum
specimen >1 mL in volume was obtained;
whenever possible, additional sputum specimens
were obtained on consecutive days.
Laboratory Testing for TB
Acid-fast Bacilli Smear Microscopy
All samples were digested and concentrat-
ed by the standard N-acetyl-L-cysteine NaOH-
Na citrate method for processing mycobacterial
specimens (8). Ziehl-Neelsen and Auramine
staining were performed by standard tech-
niques (8).
Cultures
Mycobacterial growth indicator tubes (Becton
Dickinson, Sparks, MD) containing both 10%
OADC (oleic acid, albumin, dextrose, and
catalase) (Becton Dickinson, Sparks, MD), and
100 µL of PANTA Antimicrobic Supplement
(Polymyxin B, Amphotericin B, Nalidixic acid,
Trimethoprim, and Azlocillin) (Becton Dickinson)
were injected with 500 µL of decontaminated
sputum sample according to the manufacturer’s
specifications. Löwenstein-Jensen slants (Difco,
Detroit, MI) and Middlebrook 7H11 medium
plates (Difco, Detroit, MI) were injected with
250  µL of decontaminated sample. Tubes were
incubated at 37°C and examined for mycobacte-
rial growth at least weekly for up to 6 weeks with
a 365-nm UV transilluminator. Löwenstein-
Jensen slants and micro-agar 7H11 plates were
incubated at 37°C with and without 5% CO2 and
examined by light microscopy for mycobacterial
growth at least weekly for 2 to 8 weeks after
injection (8). Criteria for positive mycobacterial
growth have been previously described by the
Centers for Disease Control (9).
Sensitivity Testing
The microplate alamar blue assay was used
to determine mycobacterial drug resistance (10).
Bacterial suspensions were prepared from
colonies grown on Middlebrook 7H11 agar.
Samples of the bacterial suspension (20 µL) were
grown in 96-well plates containing serial
dilutions of anti-TB drugs (isoniazid, rifampin,
ethambutol, streptomycin, capreomycin,
ciprofloxacin) until control wells tested positive
for mycobacterial growth, usually in 5 to 6 days.
Alamar blue reagent was then added to each well,
and mycobacterial growth was identified by a
change in media color from blue to pink. MIC was
defined as the lowest drug concentration at which
no blue-to-pink color change was observed. MICs
for the panel of six anti-TB drugs were
determined for each isolate.
Data Analysis
Patients were included in the study if they
completed the questionnaire, had a physical
examination, and provided one adequate sputum
specimen. A patient was considered to have
MDRTB if the sputum exhibited growth in media
containing both isoniazid and rifampin. HIV tests
were not performed as part of this study, but HIV
test results were available for some patients.
All data were entered twice, and the two
databases were compared to eliminate data entry
errors. Data were analyzed with SPSS version
7.5 (SPSS Inc., Chicago, IL) and Epi Info version
6.0 (CDC, Atlanta, GA). The chi-square and
Fisher’s exact tests were used to measure
strengths of association for categorical variables.
The Wilcoxon 2-sample test was used to compare
continuous variables.
Results
From January to December 1997, 250 (78%)
of 319 patients admitted to the ward had a
completed questionnaire and physical examina-
tion and at least one adequate sputum specimen.
Forty patients (16%) had sputum cultures
positive for Mycobacterium tuberculosis, and 26
of these had positive sputum smears. One patient125 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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had a positive smear but a negative culture. Only
three patients had a diagnosis of HIV infection;
none of the three had a positive sputum
specimen. Of the 69 ward patients who declined
to participate or were unable to provide an
adequate sputum specimen, 4 (6%) had been
admitted with a diagnosis of suspected TB. If we
assume all excluded patients to be negative for
TB, the minimum estimated TB prevalence on
the ward was 13%.
Patients with a cough of any duration, a
cough that lasted >2 weeks, reported weight loss,
hemoptysis, or a family history of TB were more
likely to have sputum cultures positive for TB
(Table 1). Anorexia was associated with a lower
likelihood of TB. Because of logistic constraints,
we were able to place and read a TST at 48 to 72
hours only on a subset of patients. Of the 67
patients with TST results, a positive reading was
observed in 11 (55%) of 20 culture-positive
patients compared with 10 (21%) of 47 patients
without TB (p=0.007). Among culture-positive
patients, those with a positive TST response were
younger than those with a negative reading
(median 23 years of age[range 19-66] vs. 47 years
[range 25-88], p=0.02 by Wilcoxon 2-sample test).
The socioeconomic status of patients with and
without TB was similar.
Of the 181 patients who reported past BCG
immunization, 178 (98%) had a scar. No vaccine
scars were observed among the 68 persons who
reported no history of BCG immunization.
However, having a BCG scar was not associated
with any apparent protective effect (Table 1). The
presence of a BCG scar was not associated with a
positive TST, even when TB culture positive
patients were excluded (p=0.7).
Of 40 patients with at least one positive
sputum culture, 23 (58%) had strains resistant to
at least isoniazid, 8 (20%) to rifampin, 4 (10%) to
ethambutol, and 1 (3%) to streptomycin. None
were resistant to ciprofloxacin or capreomycin.
Eight patients (20%) had TB resistant to both
isoniazid and rifampin and were classified as
having MDRTB. All 8 patients with resistance to
rifampin also had resistance to isoniazid, and 15
patients had strains resistant to isoniazid but not
to rifampin. Of the eight strains resistant to both
isoniazid and rifampin, one was also resistant to
ethambutol, one to streptomycin, and one to both
ethambutol and streptomycin. Of 8 patients with
MDRTB, 3 had a previous history of TB
treatment.
Culture-positive patients for whom TB was
the admitting diagnosis differed from those in
whom TB was not suspected at the time of
admission (Table 2). Patients whose TB had not
been suspected were older and less likely to have
the classic findings of cough, hemoptysis, weight
loss, and prior personal or family history of TB.
Patients whose TB had not been suspected at the
time of admission were less likely to have a
positive sputum smear, but this difference did
not reach statistical significance (p=0.16 by
Fisher’s exact test). However, patients whose TB
had not been suspected were significantly more
likely to have MDRTB. Six (75%) of 8 patients
with MDRTB were not suspected to have TB on
admission; 3 (50%) of these six were also smear
positive. Admitting diagnoses among culture-
positive patients whose TB had not been
suspected on admission included two patients
with diabetes mellitus, one with systemic lupus
erythematosus, and one with a lung lesion
thought to be a hydatid cyst.
Table 1. Female patients admitted to a general medicine
ward of a hospital, Lima, Peru
Mycobacterium tuberculosis
culture results
   Positive   Negativea
Characteristic N=40, n (%) N=209, n (%)
Median age (range) 43 (18-96)   46 (14-92)
Cough 35 (88)b 125 (60)b
Cough for > 2 weeks 25 (63)b   64 (31)b
Weight loss 33 (83)b 122 (58)b
Hemoptysis 12 (30)c   29 (14)c
Anorexia 22 (55)c 149 (71)c
Fever 24 (60) 108 (51)
Dyspnea 22 (55) 107 (51)
TST positived 11 (55)c   10 (21)c
BCG scar 28 (70) 150 (71)
History of BCG 29 (73) 152 (72)
  vaccination
Family history of TB 12 (30)c   32 (15) c
Prior history of TB   9 (23)   34 (16)
Socioeconomic indicators
   Electricity in home 36 (90) 196 (93)
  Piped water 32 (80) 180 (86)
  Able to read and write 31 (78) 159 (76)
aOne patient who was smear positive but culture negative
was excluded from the analysis.
bP value < 0.01 by Mantel-Haenzsel chi-square test.
cP value < 0.05 by Mantel-Haenzsel chi-square test.
dA total of 67 patients, 20 M. tuberculosis culture-positive
and 47 M. tuberculosis culture-negative, had tuberculin skin
tests (TST).126 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
Research
Conclusions
The overall prevalence of TB among our
study patients was high: at least 13% of all
patients admitted to this general medicine ward
had active TB. Two-thirds of TB patients were
smear positive and therefore highly infectious,
one-fifth had multidrug-resistant strains, and
75% of the patients with MDRTB had not been
suspected of having TB when they entered the
hospital. As in most Latin American hospitals, no
masks or other respiratory devices were used to
prevent spread in this hospital, even when the
patient was known to be smear positive and
highly infectious.
Nosocomial outbreaks of MDRTB in the
United States in the 1980s and early 1990s
heightened enforcement of stringent hospital
control measures (11), leading to measurable
decreases in TST conversion rates among
hospital staff (12). Although the rate of TB in
Peru is approximately 20 times higher than that
of New York City (13), no concerted effort has
been made to improve TB control measures in
Peruvian hospitals.
The spread of MDRTB threatens control
efforts (14). The fact that the majority of our
patients with MDRTB had no history of past
treatment of TB implies that person-to-person
transmission of multidrug resistant strains
occurs in Peru. Our data suggest that hospital
wards may be one of the sites of transmission.
In developing countries where resources are
limited, TB control programs focus on identifica-
tion and treatment of infectious cases (15).
Although treatment is clearly an important
component of control, person-to-person spread of
resistant strains makes isolation a high priority
for preventing transmission. TST testing was not
useful in identifying the group in need of
screening. Anergy, which was common among
culture-positive TB cases, was associated statisti-
cally with older median age and was perhaps
related to concurrent systemic illness and poor
nutritional status among hospitalized patients.
Although Peru has implemented an effective
community-based TB control program, hospital
control has not been a focus. Control measures
such as isolation and respiratory precautions,
stringently enforced in the past, were relaxed
worldwide after the advent of inexpensive,
effective anti-TB medications. After 50 years of
selective drug pressure, the outbreak of MDRTB
in New York City (5) dramatically highlighted
the consequences of lapses in infection control.
Our data show that in countries or locales
with a known high prevalence of TB, hospitals
should screen all patients with respiratory
symptoms by sputum smear within 12 hours of
admission to hospital. Those found to be smear-
positive should be placed in respiratory isolation,
apart from TB-negative patients, until the smear
becomes negative. Hospital personnel should
observe respiratory precautions in caring for
these patients. A system of rapid culture
diagnosis and susceptibility testing should be
implemented, allowing the presumptive diagno-
sis of MDRTB within 2 weeks (16). In
combination, admission screening for TB, re-
implementation of effective hospital respiratory
control, and rapid TB diagnosis can substantially
decrease the transmission of TB, especially
MDRTB, in countries like Peru.
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Table 2. Mycobacterium tuberculosis culture-positive
patients, by admission diagnosis, Lima, Peru
M. tuberculosis
                    culture-positive patients
Suspected TB No suspected TB
Characteristic N=27, n (%) N=13, n (%)
Median age (range) 27 (18-87)a 58 (22-96)a
Cough 27 (100)b   8 (62)b
Cough for > 2 weeks 20 (74)c   5 (39)c
Weight loss 25 (93)c   8 (62)c
Hemoptysis 10 (37)   2 (15)
Fever 16 (59)   8 (62)
Anorexia 13 (48)   9 (69)
Dyspnea 17 (63)   5 (39)
Prior history of TB   8 (30)   1 (8)
Family history of TB 10 (37)   2 (15)
Smear positive 20 (74)   6 (46)
MDRTB   2 (7)c   6 (46)c
MDRTB and smear   2 (7)   3 (23)
  positive
ap value < 0.05 by Wilcoxon 2-sample test.
bp value < 0.01 by Fisher’s exact 2-tailed test.
cp value < 0.05 by Fisher’s exact 2-tailed test.
MDRTB = Multidrug-resistant tuberculosis.127 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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